Japanese drugmaker Ono Pharmaceutical (TYO: 4528) and Poland’s Captor Therapeutics (WSE: CTX), a specialist in the development of targeted protein degradation (TPD)-based drugs, have entered a worldwide drug discovery collaboration.
The deal will see the companies link up to develop novel small molecule degrader drugs against a currently undrugged target of interest in neurodegenerative diseases.
"A testament to the promise of our discovery platform and the achievements of our R&D team as they advance our own degrader drug candidates towards the clinic"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze